index,Regulator Name,Regulator Type,Regulator Subtype,Regulator HGNC Symbol,Regulator Database,Regulator ID,Regulator Compartment,Regulator Compartment ID,Regulated Name,Regulated Type,Regulated Subtype,Regulated HGNC Symbol,Regulated Database,Regulated ID,Regulated Compartment,Regulated Compartment ID,Sign,Connection Type,Mechanism,Site,Cell Line,Cell Type,Tissue Type,Organism,Unnamed: 0,Score,Source,Statements,Paper IDs,Evidence Score,Match Score,Kind Score,Epistemic Value,Total Score
15,braf,protein,,braf,uniprot,p13547,cytoplasm,go:0005634,mek,protein,,mek1,uniprot,p00155,cytoplasm,go:0005634,positive,d,activates,,,,,human,['76'],nan,nan,"in parallel, inhibitors targeting mek (e.g., selumetinib, trametinib, cobimetinib) have been developed. braf's unique effector is mek, and pre-clinical studies have shown that braf mutant cells are significantly more sensitive to mek inhibition inhibitors than ras mutant cells (solit et al., 2006), probably due to ras activating other pathways such as the pi3k-cascade to promote cell survival (haass et al., 2008). despite drug related toxicities limiting the use of mek inhibitors, recently developed highly potent inhibitors show efficacy in patients (flaherty et al., 2012; kirkwood et al., 2012; ascierto et al., 2013).",pmc4846800,1,10,7,1,17
92,mek,protein,,map2k1,uniprot,q96787,cytoplasm,go:0005736,erk,protein,,mapk3,uniprot,p00432,cytoplasm,go:0005736,positive,d,inhibition,,,,,human,['88'],nan,nan,"an alternative combination that is currently in clinical trials is the combined inhibition of mek and erk (nct02457793). the rationale behind this combination is the notion that resistance to targeted inhibition of raf and mek often involves reactivation of erk (ryan et al., 2015), while suboptimal suppression of erk activity in raf mutant cancers may underlie theÂ limited efficacy (bollag et al., 2010; corcoran et al., 2015). although our ras mutant crc organoids showed sensitivity to dual inhibition of mek and erk, also this drug combination induced cell-cycle arrest rather than cell death, questioning whether it will be sufficient for the treatment of ras mutant crc.",pmc5127645,1,10,7,1,17
